Raphael Pharmaceutical signs 12-month AI transformation deal with AIcreatesAI for $180K

Raphael Pharmaceutical Inc.

Agreement effective July 30, 2026; AIcreatesAI serves as managed AI transformation, commercialization, and growth partner for 12 months.
Annual fee of $180,000 payable in $15,000 monthly installments; unpaid invoices defer until financing, capital, or revenues arrive.
Company may issue common shares to satisfy deferred payments with AIcreatesAI's written consent, subject to securities laws and OTC Markets rules.
AIcreatesAI entitled to 2% of net profits from any company-branded digital token platform, separate from the service fee and subject to board approval.
Services include website/app/CRM development, marketing, research intelligence, partnership development, and investor communications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.